サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1536175

むずむず脚症候群の世界市場

Restless Legs Syndrome

出版日
ページ情報
英文 290 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
むずむず脚症候群の世界市場
出版日: 2024年08月16日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 290 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

むずむず脚症候群の世界市場は2030年までに8億1,180万米ドルに達する見込み

2023年に6億3,770万米ドルと推定されたむずむず脚症候群の世界市場は、2030年には8億1,180万米ドルに達し、分析期間2023-2030年のCAGRは3.5%で成長すると予測されます。本レポートで分析されているセグメントの1つである薬とデバイスは、CAGR 4.0％を記録し、分析期間終了時には5億6,290万米ドルに達すると予測されています。外科分野の成長率は、分析期間中CAGR 2.5％と推定されます。

米国市場は1億7,370万米ドルと推定、中国はCAGR6.8%で成長予測

米国のむずむず脚症候群市場は、2023年に1億7,370万米ドルと推定されます。世界第2位の経済大国である中国は、2023年から2030年にかけてCAGR 6.8%で推移し、2030年には1億6,950万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.1%と2.7%と予測されています。欧州では、ドイツがCAGR 1.9%で成長すると予測されています。

主要動向と促進要因

むずむず脚症候群（RLS）はウィリス・エクボム病としても知られ、足を動かしたいという制御不能な衝動を特徴とする神経疾患です。症状は一般に、安静時または運動不足時、特に夜間に発現し、睡眠を著しく妨げ、生活の質を低下させる。RLSは、米国では成人の約5～10％が罹患しており、女性と高齢者で有病率が高いです。RLSの正確な原因は不明であるが、筋肉の動きを調節する神経伝達物質であるドーパミンの不均衡や、おそらく鉄欠乏が関係していると考えられています。この疾患は、特発性（原因が特定されていない）の場合もあれば、妊娠、鉄欠乏、腎不全などの他の疾患に続発する場合もあります。

RLSの治療には、通常、生活習慣の改善、薬理学的治療、鉄欠乏がある場合は鉄の補給を組み合わせて行う。生活習慣への介入には、規則正しい睡眠パターンの維持、適度な運動、カフェインやアルコールの摂取を避けることなどが含まれます。薬物療法は、主にプラミペキソールやロピニロールなどのドパミン作用を増強する薬剤を用いますが、重症例ではガバペンチンやオピオイドを用いることもあります。これらの治療はRLSを完治させるものではないが、症状を大幅に緩和し、睡眠と生活の質を改善します。しかし、ドパミン作動性薬物を長期的に使用すると、増強-治療前よりも症状が悪化する状態-が起こる可能性があります。この逆説的な作用は、慢性RLS管理における重要な課題となるため、定期的な評価と治療法の調整が必要となります。

むずむず脚症候群市場の成長は、RLS症例の特定と報告を増加させる認知度の向上や診断方法の改善など、いくつかの要因によって牽引されています。神経学と睡眠医学の進歩は理解と治療の向上に寄与し、市場の成長を促進します。神経疾患を患いやすい世界人口の高齢化も、RLS治療の患者層を拡大しています。さらに、RLSの病態生理学の研究が進むことで、より的を絞った治療法の開発が期待され、現在のドパミン作動性治療でみられる増強のリスクを軽減できる可能性があります。この市場は、ヘルスケア支出の増加と睡眠障害に対する償還政策の拡大から恩恵を受け、薬理学的療法と非薬理学的療法の両方の採用を促進しています。さらに、睡眠と運動をモニターするウェアラブルデバイスのようなデジタルヘルス技術革新は、RLSの管理に不可欠なものとなりつつあり、技術開発者とヘルスケアプロバイダーに新たな成長機会を提供しています。このような進歩によりRLS治療が進化するにつれ、市場は持続的な成長を遂げ、世界中の患者の予後を改善することが期待されます。

調査対象企業の例（全86件）

  • Azurity Pharmaceuticals, Inc.
  • Boehringer Ingelheim International GmbH
  • Emalex Biosciences, Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Relegs BV
  • UCB SA

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP27120

Global Restless Legs Syndrome Market to Reach US$811.8 Million by 2030

The global market for Restless Legs Syndrome estimated at US$637.7 Million in the year 2023, is expected to reach US$811.8 Million by 2030, growing at a CAGR of 3.5% over the analysis period 2023-2030. Medication & Devices, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$562.9 Million by the end of the analysis period. Growth in the Surgery segment is estimated at 2.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$173.7 Million While China is Forecast to Grow at 6.8% CAGR

The Restless Legs Syndrome market in the U.S. is estimated at US$173.7 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$169.5 Million by the year 2030 trailing a CAGR of 6.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.1% and 2.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR.

Key Trends and Drivers

Restless Legs Syndrome (RLS), also known as Willis-Ekbom Disease, is a neurological disorder characterized by an uncontrollable urge to move the legs, typically due to unpleasant sensations described as crawling, tingling, or burning. The symptoms generally occur during periods of rest or inactivity, particularly at night, and can severely disrupt sleep and reduce quality of life. RLS affects approximately 5 to 10% of adults in the U.S., with a higher prevalence in women and older adults. The exact cause of RLS is unknown, but it is believed to be associated with imbalances in dopamine, a neurotransmitter that regulates muscle movement, and possibly iron deficiency. The condition can be idiopathic (having no identified cause) or secondary to other conditions such as pregnancy, iron deficiency, or renal failure.

Treatment for RLS typically involves a combination of lifestyle changes, pharmacological treatments, and sometimes iron supplementation if deficiency is present. Lifestyle interventions include maintaining regular sleep patterns, exercising moderately, and avoiding caffeine and alcohol. Medications used are mainly dopaminergic agents that increase dopamine effects, such as pramipexole and ropinirole, but can also include gabapentin and opioids for more severe cases. While these treatments do not cure RLS, they significantly alleviate symptoms and improve sleep and quality of life. However, long-term use of dopaminergic drugs can lead to augmentation—a condition where symptoms become worse than before treatment. This paradoxical effect poses a significant challenge in chronic RLS management, necessitating periodic evaluation and adjustment of therapy.

The growth in the Restless Legs Syndrome market is driven by several factors including heightened awareness and better diagnostic practices which increase the identification and reporting of RLS cases. Advances in neurology and sleep medicine contribute to improved understanding and treatments, enhancing market growth. An aging global population prone to neurological disorders also expands the patient base for RLS treatments. Additionally, ongoing research into the pathophysiology of RLS promises the development of more targeted therapies, potentially reducing the risk of augmentation seen with current dopaminergic treatments. The market benefits from increased healthcare spending and expanding reimbursement policies for sleep disorders, encouraging the adoption of both pharmacologic and non-pharmacologic therapies. Moreover, digital health innovations, like wearable devices monitoring sleep and movement, are becoming integral in managing RLS, offering new growth opportunities for technology developers and healthcare providers alike. As the landscape of RLS treatment evolves with these advancements, the market is expected to see sustained growth, improving outcomes for patients worldwide.

Select Competitors (Total 86 Featured) -

  • Azurity Pharmaceuticals, Inc.
  • Boehringer Ingelheim International GmbH
  • Emalex Biosciences, Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Relegs BV
  • UCB SA

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Restless Legs Syndrome - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Prevalence of Restless Legs Syndrome
    • Advances in Neurological Research
    • Growing Awareness of Restless Legs Syndrome
    • Development of New Therapeutic Options
    • Impact of Lifestyle Changes on Disease Incidence
    • Rising Geriatric Population
    • Increasing Diagnosis Rates
    • Adoption of Novel Drug Delivery Systems
    • Expansion of Research on Comorbid Conditions
    • Growing Investment in Drug Development
    • Favorable Reimbursement Policies
    • Technological Innovations in Diagnosis and Treatment
    • Market Penetration of Non-Pharmacological Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Restless Legs Syndrome Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Restless Legs Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Restless Legs Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Restless Legs Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Medication & Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Medication & Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Medication & Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Surgery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Homecare End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Homecare End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Homecare End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Restless Legs Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Restless Legs Syndrome by Type - Medication & Devices and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Restless Legs Syndrome by Type - Medication & Devices and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Restless Legs Syndrome by Type - Percentage Breakdown of Value Sales for Medication & Devices and Surgery for the Years 2014, 2024 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Restless Legs Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Restless Legs Syndrome by Type - Medication & Devices and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Restless Legs Syndrome by Type - Medication & Devices and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Restless Legs Syndrome by Type - Percentage Breakdown of Value Sales for Medication & Devices and Surgery for the Years 2014, 2024 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Restless Legs Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • JAPAN
    • Restless Legs Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Restless Legs Syndrome by Type - Medication & Devices and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Restless Legs Syndrome by Type - Medication & Devices and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Restless Legs Syndrome by Type - Percentage Breakdown of Value Sales for Medication & Devices and Surgery for the Years 2014, 2024 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Restless Legs Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • CHINA
    • Restless Legs Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Restless Legs Syndrome by Type - Medication & Devices and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Restless Legs Syndrome by Type - Medication & Devices and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: China 16-Year Perspective for Restless Legs Syndrome by Type - Percentage Breakdown of Value Sales for Medication & Devices and Surgery for the Years 2014, 2024 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: China 16-Year Perspective for Restless Legs Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • EUROPE
    • Restless Legs Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Restless Legs Syndrome by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Restless Legs Syndrome by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Restless Legs Syndrome by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Restless Legs Syndrome by Type - Medication & Devices and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Restless Legs Syndrome by Type - Medication & Devices and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Restless Legs Syndrome by Type - Percentage Breakdown of Value Sales for Medication & Devices and Surgery for the Years 2014, 2024 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Restless Legs Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • FRANCE
    • Restless Legs Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Restless Legs Syndrome by Type - Medication & Devices and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Restless Legs Syndrome by Type - Medication & Devices and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: France 16-Year Perspective for Restless Legs Syndrome by Type - Percentage Breakdown of Value Sales for Medication & Devices and Surgery for the Years 2014, 2024 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: France 16-Year Perspective for Restless Legs Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • GERMANY
    • Restless Legs Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Restless Legs Syndrome by Type - Medication & Devices and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Restless Legs Syndrome by Type - Medication & Devices and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Restless Legs Syndrome by Type - Percentage Breakdown of Value Sales for Medication & Devices and Surgery for the Years 2014, 2024 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Restless Legs Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Restless Legs Syndrome by Type - Medication & Devices and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Restless Legs Syndrome by Type - Medication & Devices and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Restless Legs Syndrome by Type - Percentage Breakdown of Value Sales for Medication & Devices and Surgery for the Years 2014, 2024 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Restless Legs Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Restless Legs Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Restless Legs Syndrome by Type - Medication & Devices and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Restless Legs Syndrome by Type - Medication & Devices and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Restless Legs Syndrome by Type - Percentage Breakdown of Value Sales for Medication & Devices and Surgery for the Years 2014, 2024 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Restless Legs Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Restless Legs Syndrome by Type - Medication & Devices and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Restless Legs Syndrome by Type - Medication & Devices and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Restless Legs Syndrome by Type - Percentage Breakdown of Value Sales for Medication & Devices and Surgery for the Years 2014, 2024 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Restless Legs Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Restless Legs Syndrome by Type - Medication & Devices and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Restless Legs Syndrome by Type - Medication & Devices and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Restless Legs Syndrome by Type - Percentage Breakdown of Value Sales for Medication & Devices and Surgery for the Years 2014, 2024 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Restless Legs Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Restless Legs Syndrome by Type - Medication & Devices and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Restless Legs Syndrome by Type - Medication & Devices and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Restless Legs Syndrome by Type - Percentage Breakdown of Value Sales for Medication & Devices and Surgery for the Years 2014, 2024 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Restless Legs Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Restless Legs Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Restless Legs Syndrome by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Restless Legs Syndrome by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Restless Legs Syndrome by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Restless Legs Syndrome by Type - Medication & Devices and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Restless Legs Syndrome by Type - Medication & Devices and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Restless Legs Syndrome by Type - Percentage Breakdown of Value Sales for Medication & Devices and Surgery for the Years 2014, 2024 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Restless Legs Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Restless Legs Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Restless Legs Syndrome by Type - Medication & Devices and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Restless Legs Syndrome by Type - Medication & Devices and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Restless Legs Syndrome by Type - Percentage Breakdown of Value Sales for Medication & Devices and Surgery for the Years 2014, 2024 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Restless Legs Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • INDIA
    • Restless Legs Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Restless Legs Syndrome by Type - Medication & Devices and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Restless Legs Syndrome by Type - Medication & Devices and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: India 16-Year Perspective for Restless Legs Syndrome by Type - Percentage Breakdown of Value Sales for Medication & Devices and Surgery for the Years 2014, 2024 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: India 16-Year Perspective for Restless Legs Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Restless Legs Syndrome by Type - Medication & Devices and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Restless Legs Syndrome by Type - Medication & Devices and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Restless Legs Syndrome by Type - Percentage Breakdown of Value Sales for Medication & Devices and Surgery for the Years 2014, 2024 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Restless Legs Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Restless Legs Syndrome by Type - Medication & Devices and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Restless Legs Syndrome by Type - Medication & Devices and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Restless Legs Syndrome by Type - Percentage Breakdown of Value Sales for Medication & Devices and Surgery for the Years 2014, 2024 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Restless Legs Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Restless Legs Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Restless Legs Syndrome by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Restless Legs Syndrome by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Restless Legs Syndrome by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Restless Legs Syndrome by Type - Medication & Devices and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Restless Legs Syndrome by Type - Medication & Devices and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Restless Legs Syndrome by Type - Percentage Breakdown of Value Sales for Medication & Devices and Surgery for the Years 2014, 2024 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Restless Legs Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Restless Legs Syndrome by Type - Medication & Devices and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Restless Legs Syndrome by Type - Medication & Devices and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Restless Legs Syndrome by Type - Percentage Breakdown of Value Sales for Medication & Devices and Surgery for the Years 2014, 2024 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Restless Legs Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Restless Legs Syndrome by Type - Medication & Devices and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Restless Legs Syndrome by Type - Medication & Devices and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Restless Legs Syndrome by Type - Percentage Breakdown of Value Sales for Medication & Devices and Surgery for the Years 2014, 2024 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Restless Legs Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Restless Legs Syndrome by Type - Medication & Devices and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Restless Legs Syndrome by Type - Medication & Devices and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Restless Legs Syndrome by Type - Percentage Breakdown of Value Sales for Medication & Devices and Surgery for the Years 2014, 2024 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Restless Legs Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Restless Legs Syndrome by Type - Medication & Devices and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Restless Legs Syndrome by Type - Medication & Devices and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Restless Legs Syndrome by Type - Percentage Breakdown of Value Sales for Medication & Devices and Surgery for the Years 2014, 2024 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Restless Legs Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Restless Legs Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Restless Legs Syndrome by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Restless Legs Syndrome by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Restless Legs Syndrome by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Restless Legs Syndrome by Type - Medication & Devices and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Restless Legs Syndrome by Type - Medication & Devices and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Restless Legs Syndrome by Type - Percentage Breakdown of Value Sales for Medication & Devices and Surgery for the Years 2014, 2024 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Restless Legs Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Restless Legs Syndrome by Type - Medication & Devices and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Restless Legs Syndrome by Type - Medication & Devices and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Restless Legs Syndrome by Type - Percentage Breakdown of Value Sales for Medication & Devices and Surgery for the Years 2014, 2024 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Restless Legs Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Restless Legs Syndrome by Type - Medication & Devices and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Restless Legs Syndrome by Type - Medication & Devices and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Restless Legs Syndrome by Type - Percentage Breakdown of Value Sales for Medication & Devices and Surgery for the Years 2014, 2024 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Restless Legs Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Restless Legs Syndrome by Type - Medication & Devices and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Restless Legs Syndrome by Type - Medication & Devices and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Restless Legs Syndrome by Type - Percentage Breakdown of Value Sales for Medication & Devices and Surgery for the Years 2014, 2024 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Restless Legs Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Restless Legs Syndrome by Type - Medication & Devices and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Restless Legs Syndrome by Type - Medication & Devices and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Restless Legs Syndrome by Type - Percentage Breakdown of Value Sales for Medication & Devices and Surgery for the Years 2014, 2024 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Restless Legs Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Restless Legs Syndrome by Type - Medication & Devices and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Restless Legs Syndrome by Type - Medication & Devices and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Restless Legs Syndrome by Type - Percentage Breakdown of Value Sales for Medication & Devices and Surgery for the Years 2014, 2024 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Restless Legs Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • AFRICA
    • Restless Legs Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Restless Legs Syndrome by Type - Medication & Devices and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Restless Legs Syndrome by Type - Medication & Devices and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Restless Legs Syndrome by Type - Percentage Breakdown of Value Sales for Medication & Devices and Surgery for the Years 2014, 2024 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Restless Legs Syndrome by End-Use - Hospitals End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Restless Legs Syndrome by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030

IV. COMPETITION